Ixabepilone: Difference between revisions

From WikiMD's Wellness Encyclopedia

Deepika vegiraju (talk | contribs)
No edit summary
 
No edit summary
 
Line 1: Line 1:
   
  == '''What is Ixabepilone?''' ==
 
== '''What is Ixabepilone?''' ==


* Ixabepilone ('''Ixempra''') is '''a microtubule inhibitor''' used to treat [[metastatic]] or locally advanced [[breast cancer]] that has not improved after treatment with certain other anticancer drugs.  
* Ixabepilone ('''Ixempra''') is '''a microtubule inhibitor''' used to treat [[metastatic]] or locally advanced [[breast cancer]] that has not improved after treatment with certain other anticancer drugs.  
Line 9: Line 7:


[[File:Ixabepilone functional group.svg|thumb|Ixabepilone functional group]]
[[File:Ixabepilone functional group.svg|thumb|Ixabepilone functional group]]


<youtube>
<youtube>
Line 20: Line 17:
height=600
height=600
</youtube>
</youtube>


== '''What are the uses of this medicine?''' ==
== '''What are the uses of this medicine?''' ==


Ixabepilone ('''Ixempra''') is used alone or with another cancer medicine called [[capecitabine]] to treat locally advanced [[breast cancer]] or breast cancer that has spread to other parts of the body ([[metastatic]]), when certain other medicines have not worked or no longer work.
Ixabepilone ('''Ixempra''') is used alone or with another cancer medicine called [[capecitabine]] to treat locally advanced [[breast cancer]] or breast cancer that has spread to other parts of the body ([[metastatic]]), when certain other medicines have not worked or no longer work.


== '''How does this medicine work?''' ==
== '''How does this medicine work?''' ==
<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v=vgM_km7hbUg
embed_source_url=http://www.youtube.com/v=vgM_km7hbUg
&rel=1
wrap = yes
width=750
height=600
</youtube>


* Ipilimumab (ip” i lim’ ue mab) is '''a human recombinant monoclonal immunoglobulin G1 antibody to the cytotoxic T lymphocyte antigen-4 (CTLA-4)''' which is used in cancer [[immunotherapy]].   
* Ipilimumab (ip” i lim’ ue mab) is '''a human recombinant monoclonal immunoglobulin G1 antibody to the cytotoxic T lymphocyte antigen-4 (CTLA-4)''' which is used in cancer [[immunotherapy]].   
Line 44: Line 29:
* The subsequent enhancement of cytotoxic reactivity may play a beneficial role in cancer immunotherapy and can break immunological tolerance.   
* The subsequent enhancement of cytotoxic reactivity may play a beneficial role in cancer immunotherapy and can break immunological tolerance.   
* In several large multicenter studies, ipilimumab therapy resulted in a prolongation of survival in patients with advanced, metastatic or unresectable [[malignant melanoma]], and a proportion of patients had a long term remission.  
* In several large multicenter studies, ipilimumab therapy resulted in a prolongation of survival in patients with advanced, metastatic or unresectable [[malignant melanoma]], and a proportion of patients had a long term remission.  


== '''Who Should Not Use this medicine ?''' ==
== '''Who Should Not Use this medicine ?''' ==
Line 52: Line 36:
are allergic to a medicine, such as TAXOL®, that contains [[Cremophor]]® EL or polyoxyethylated castor oil.
are allergic to a medicine, such as TAXOL®, that contains [[Cremophor]]® EL or polyoxyethylated castor oil.
are also taking a cancer medicine called [[capecitabine]] and you have liver problems.
are also taking a cancer medicine called [[capecitabine]] and you have liver problems.


== '''What drug interactions can this medicine cause?''' ==
== '''What drug interactions can this medicine cause?''' ==
Line 69: Line 52:
* [[rifampin]] (Rifadin, Rimactane, in Rifamate and Rifater)
* [[rifampin]] (Rifadin, Rimactane, in Rifamate and Rifater)
* [[verapamil]] (Calan, Covera, Isoptin, Verelan, in Tarka).  
* [[verapamil]] (Calan, Covera, Isoptin, Verelan, in Tarka).  


== '''Is this medicine FDA approved?''' ==
== '''Is this medicine FDA approved?''' ==


* Ixabepilone was approved for use in the United States in 2007 and current indications are for locally advanced or [[metastatic breast cancer]] given as [[monotherapy]] or in combination with [[capecitabine]] after failure of other treatments.  
* Ixabepilone was approved for use in the United States in 2007 and current indications are for locally advanced or [[metastatic breast cancer]] given as [[monotherapy]] or in combination with [[capecitabine]] after failure of other treatments.  


== '''How should this medicine be used?''' ==
== '''How should this medicine be used?''' ==
Line 88: Line 69:
* Ixempra is usually given 1 time every 3 weeks.  
* Ixempra is usually given 1 time every 3 weeks.  
* Each treatment with Ixempra will take about 3 hour.
* Each treatment with Ixempra will take about 3 hour.


== '''What are the  dosage forms and brand names of this medicine?''' ==
== '''What are the  dosage forms and brand names of this medicine?''' ==
Line 98: Line 78:
This medicine is available in fallowing brand namesː
This medicine is available in fallowing brand namesː
* '''Ixempra'''
* '''Ixempra'''


=='''What side effects can this medication cause?'''==
=='''What side effects can this medication cause?'''==
Line 117: Line 96:
* the skin may become dry and peel.
* the skin may become dry and peel.
* numbness and tingling
* numbness and tingling
* Ixempra may cause fertility problems in females and males, which may affect your ability to have children.
* Ixempra may cause fertility problems in females and males, which may affect your ability to have children.


Line 125: Line 103:
* Allergic reactions
* Allergic reactions
* Heart problems
* Heart problems
==''' What special precautions should I follow?''' ==
==''' What special precautions should I follow?''' ==


Line 137: Line 113:
* The alcohol content in a dose of Ixempra may affect the [[central nervous system]]. This may include impairment of a patient's ability to drive or use machines immediately after infusion.  
* The alcohol content in a dose of Ixempra may affect the [[central nervous system]]. This may include impairment of a patient's ability to drive or use machines immediately after infusion.  
* Ixabepilone stops the growth of tumor cells by blocking cell division. It is a type of [[epothilone]] analog. Also called BMS-247550 and Ixempra.
* Ixabepilone stops the growth of tumor cells by blocking cell division. It is a type of [[epothilone]] analog. Also called BMS-247550 and Ixempra.
== '''What to do in case of emergency/overdose?''' ==
== '''What to do in case of emergency/overdose?''' ==


Line 146: Line 120:
* musculoskeletal pain/[[myalgia]]
* musculoskeletal pain/[[myalgia]]
* gastrointestinal symptoms ([[nausea]], [[anorexia]], [[diarrhea]], abdominal pain, [[stomatitis]])
* gastrointestinal symptoms ([[nausea]], [[anorexia]], [[diarrhea]], abdominal pain, [[stomatitis]])


'''Management of overdosage:'''
'''Management of overdosage:'''
* There is no known [[antidote]] for overdosage of Ixempra.  
* There is no known [[antidote]] for overdosage of Ixempra.  
* In case of overdosage, closely monitor patients for adverse reactions and provide supportive treatment as clinically indicated.
* In case of overdosage, closely monitor patients for adverse reactions and provide supportive treatment as clinically indicated.


== '''Can this medicine be used in pregnancy?''' ==
== '''Can this medicine be used in pregnancy?''' ==
Line 157: Line 129:
* Based on findings in animals and its mechanism of action, Ixempra can cause fetal harm when administered to a pregnant woman.
* Based on findings in animals and its mechanism of action, Ixempra can cause fetal harm when administered to a pregnant woman.
* Advise females of reproductive potential and pregnant women of the potential risk to a fetus.
* Advise females of reproductive potential and pregnant women of the potential risk to a fetus.


=='''Can this medicine be used in children?'''==
=='''Can this medicine be used in children?'''==
Line 163: Line 134:
* The alcohol content of Ixempra should be taken into account when given to pediatric patient.
* The alcohol content of Ixempra should be taken into account when given to pediatric patient.
* It is not known if Ixempra is safe and effective in children.
* It is not known if Ixempra is safe and effective in children.


== '''What are the active and inactive ingredients in this medicine?''' ==
== '''What are the active and inactive ingredients in this medicine?''' ==
Line 169: Line 139:
* '''Active ingredient:''' ixabepilone
* '''Active ingredient:''' ixabepilone
* '''Inactive ingredients:''' The DILUENT for Ixempra contains purified polyoxyethylated castor oil and dehydrated alcohol.
* '''Inactive ingredients:''' The DILUENT for Ixempra contains purified polyoxyethylated castor oil and dehydrated alcohol.


== '''Who manufactures and distributes this medicine?''' ==
== '''Who manufactures and distributes this medicine?''' ==
Line 176: Line 145:
* DILUENT for Ixempra Manufactured by: Baxter Oncology GmbH, Halle/ Westfalen, Germany
* DILUENT for Ixempra Manufactured by: Baxter Oncology GmbH, Halle/ Westfalen, Germany
* Distributed by [[R-Pharm|R-Pharm US LLC]], Princeton, NJ USA
* Distributed by [[R-Pharm|R-Pharm US LLC]], Princeton, NJ USA


== '''What should I know about storage and disposal of this medication?''' ==
== '''What should I know about storage and disposal of this medication?''' ==
Line 184: Line 152:
* Ixempra is a hazardous drug.  
* Ixempra is a hazardous drug.  
* Follow applicable special handling and disposal procedures.
* Follow applicable special handling and disposal procedures.


{{cancer drugs}} 
{{cancer drugs}} 
{{coststubd}}}
{{coststubd}}}
{{Chemotherapeutic agents}}
{{Chemotherapeutic agents}}
[[Category:Bristol Myers Squibb]]
[[Category:Bristol Myers Squibb]]
[[Category:Mitotic inhibitors]]
[[Category:Mitotic inhibitors]]

Latest revision as of 08:27, 27 March 2025

== What is Ixabepilone? ==
  • Ixabepilone (Ixempra) is a microtubule inhibitor used to treat metastatic or locally advanced breast cancer that has not improved after treatment with certain other anticancer drugs.
  • It is also being studied in the treatment of other types of cancer.
Ixabepilone
Ixabepilone functional group

What are the uses of this medicine?[edit]

Ixabepilone (Ixempra) is used alone or with another cancer medicine called capecitabine to treat locally advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), when certain other medicines have not worked or no longer work.

How does this medicine work?[edit]

  • Ipilimumab (ip” i lim’ ue mab) is a human recombinant monoclonal immunoglobulin G1 antibody to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which is used in cancer immunotherapy.
  • The CTLA-4 antigen is an important check-point molecule that modulates and down regulates T cell responses.
  • Inhibition of CTLA on the surface of activated T cells prevents its binding to the costimulatory factor B7, which allows for a continued activation and proliferation of T cells.
  • The subsequent enhancement of cytotoxic reactivity may play a beneficial role in cancer immunotherapy and can break immunological tolerance.
  • In several large multicenter studies, ipilimumab therapy resulted in a prolongation of survival in patients with advanced, metastatic or unresectable malignant melanoma, and a proportion of patients had a long term remission.

Who Should Not Use this medicine ?[edit]

This medicine cannot be used in patients who: have low white blood cell or platelet counts. Your healthcare provider will check your blood counts. are allergic to a medicine, such as TAXOL®, that contains Cremophor® EL or polyoxyethylated castor oil. are also taking a cancer medicine called capecitabine and you have liver problems.

What drug interactions can this medicine cause?[edit]

Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following:

Is this medicine FDA approved?[edit]

How should this medicine be used?[edit]

  • Patients who experienced a hypersensitivity reaction to Ixempra require premedication with corticosteroids (eg, dexamethasone 20 mg intravenously, 30 minutes before infusion or orally, 60 minutes before infusion) in addition to pretreatment with H 1 and H 2 antagonists.

Recommended dosage:

  • The recommended dosage of Ixempra is 40 mg/m 2 administered as a 3-hour intravenous infusion once every 3 weeks.
  • Dose reduction is required in patients with elevated AST, ALT, or bilirubin.

Administration:

  • Ixempra is given by an injection directly into your vein (intravenous infusion).
  • Ixempra is usually given 1 time every 3 weeks.
  • Each treatment with Ixempra will take about 3 hour.

What are the dosage forms and brand names of this medicine?[edit]

This medicine is available in fallowing doasage form:

  • As Ixempra for injection, 15 mg supplied with DILUENT for Ixempra, 8 mL
  • Ixempra for injection, 45 mg supplied with DILUENT for Ixempra, 23.5 mL

This medicine is available in fallowing brand namesː

  • Ixempra

What side effects can this medication cause?[edit]

The most common side effects of this medicine include:

  • tiredness
  • loss of appetite
  • disorders of toenails and fingernails
  • hair loss
  • fever
  • decreased red blood cell count (anemia)
  • joint and muscle pain
  • headache
  • decreased platelet count (thrombocytopenia)
  • nausea, vomiting, diarrhea, constipation, and abdominal pain
  • sores on the lip, in the mouth and esophagus
  • tender, red palms and soles of feet (hand-foot syndrome) that looks like a sunburn
  • the skin may become dry and peel.
  • numbness and tingling
  • Ixempra may cause fertility problems in females and males, which may affect your ability to have children.

Ixempra may cause serious side effects including:

What special precautions should I follow?[edit]

  • Severe, life-threatening, or fatal myelosuppression can occur in patients treated with Ixempra. Neutropenia, febrile neutropenia, and infections have occurred. Monitor blood cell counts before and during treatment with Ixempra. Withhold, reduce, or discontinue Ixempra depending on severity.
  • Peripheral neuropathy (sensory and motor neuropathy) occurred in patients treated with Ixempra in combination with capecitabine and in patients treated with single agent Ixempra. Monitor for symptoms of neuropathy (sensory and motor neuropathy). Withhold, reduce, or discontinue Ixempra depending on severity.
  • Increased toxicity in patients with hepatic impairment. Grade 4 neutropenia, febrile neutropenia, and serious adverse reactions may occur in patients with hepatic impairment during treatment with Ixempra. Reduce dose depending on severity.
  • Ixempra is contraindicated in patients with a history of a severe hypersensitivity reaction to agents containing Cremophor ® EL or its derivatives (eg, polyoxyethylated castor oil). Severe hypersensitivity reactions (including anaphylaxis) have occurred. Premedicate all patients before treatment with Ixempra. Withhold, reduce, or discontinue Ixempra depending on severity.
  • Cardiac adverse reactions (myocardial ischemia and ventricular dysfunction) occurred in patients receiving Ixempra. Closely monitor patients with a history of cardiac disease during treatment with Ixempra. Consider discontinuation of Ixempra in patients who develop cardiac ischemia or impaired cardiac function.
  • Based on findings in animals and its mechanism of action, Ixempra can cause fetal harm when administered to a pregnant woman. Advise patients of potential risk to a fetus and to use effective contraception.
  • The alcohol content in a dose of Ixempra may affect the central nervous system. This may include impairment of a patient's ability to drive or use machines immediately after infusion.
  • Ixabepilone stops the growth of tumor cells by blocking cell division. It is a type of epothilone analog. Also called BMS-247550 and Ixempra.

What to do in case of emergency/overdose?[edit]

Symptoms of overdosage may include:

Management of overdosage:

  • There is no known antidote for overdosage of Ixempra.
  • In case of overdosage, closely monitor patients for adverse reactions and provide supportive treatment as clinically indicated.

Can this medicine be used in pregnancy?[edit]

  • Based on findings in animals and its mechanism of action, Ixempra can cause fetal harm when administered to a pregnant woman.
  • Advise females of reproductive potential and pregnant women of the potential risk to a fetus.

Can this medicine be used in children?[edit]

  • The alcohol content of Ixempra should be taken into account when given to pediatric patient.
  • It is not known if Ixempra is safe and effective in children.

What are the active and inactive ingredients in this medicine?[edit]

  • Active ingredient: ixabepilone
  • Inactive ingredients: The DILUENT for Ixempra contains purified polyoxyethylated castor oil and dehydrated alcohol.

Who manufactures and distributes this medicine?[edit]

  • Ixempra ® (ixabepilone) for injection Manufactured by: Baxter Oncology GmbH, Halle/Westfalen, Germany
  • DILUENT for Ixempra Manufactured by: Baxter Oncology GmbH, Halle/ Westfalen, Germany
  • Distributed by R-Pharm US LLC, Princeton, NJ USA

What should I know about storage and disposal of this medication?[edit]

  • Ixempra Kit must be stored in a refrigerator at 2° C to 8° C (36° F to 46° F).
  • Retain in original package until time of use to protect from light.
  • Ixempra is a hazardous drug.
  • Follow applicable special handling and disposal procedures.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ